ZA891403B - Occlusive body for administering a physiologically active substance - Google Patents

Occlusive body for administering a physiologically active substance

Info

Publication number
ZA891403B
ZA891403B ZA891403A ZA891403A ZA891403B ZA 891403 B ZA891403 B ZA 891403B ZA 891403 A ZA891403 A ZA 891403A ZA 891403 A ZA891403 A ZA 891403A ZA 891403 B ZA891403 B ZA 891403B
Authority
ZA
South Africa
Prior art keywords
administering
active substance
physiologically active
occlusive body
occlusive
Prior art date
Application number
ZA891403A
Other languages
English (en)
Inventor
John Mark Tucker
Mark Tucker John
Mark Rupert Tucker
Rupert Tucker Mark
Original Assignee
Mark Tucker John
Rupert Tucker Mark
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Mark Tucker John, Rupert Tucker Mark filed Critical Mark Tucker John
Publication of ZA891403B publication Critical patent/ZA891403B/xx

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/70—Web, sheet or filament bases ; Films; Fibres of the matrix type containing drug
    • A61K9/7023—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms
    • A61K9/703—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms characterised by shape or structure; Details concerning release liner or backing; Refillable patches; User-activated patches
    • A61K9/7084—Transdermal patches having a drug layer or reservoir, and one or more separate drug-free skin-adhesive layers, e.g. between drug reservoir and skin, or surrounding the drug reservoir; Liquid-filled reservoir patches

Landscapes

  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Dermatology (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Preparation (AREA)
  • Materials For Medical Uses (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
ZA891403A 1988-02-23 1989-02-23 Occlusive body for administering a physiologically active substance ZA891403B (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GB888804164A GB8804164D0 (en) 1988-02-23 1988-02-23 Bandage for administering physiologically active compound

Publications (1)

Publication Number Publication Date
ZA891403B true ZA891403B (en) 1989-11-29

Family

ID=10632193

Family Applications (1)

Application Number Title Priority Date Filing Date
ZA891403A ZA891403B (en) 1988-02-23 1989-02-23 Occlusive body for administering a physiologically active substance

Country Status (11)

Country Link
US (1) US5254346A (enExample)
EP (2) EP0508979B1 (enExample)
JP (1) JP2716231B2 (enExample)
KR (1) KR970009723B1 (enExample)
AU (1) AU618085B2 (enExample)
DE (1) DE68915291T2 (enExample)
ES (1) ES2052071T3 (enExample)
GB (1) GB8804164D0 (enExample)
IN (1) IN172748B (enExample)
WO (1) WO1989007959A1 (enExample)
ZA (1) ZA891403B (enExample)

Families Citing this family (172)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4849224A (en) * 1987-11-12 1989-07-18 Theratech Inc. Device for administering an active agent to the skin or mucosa
JPH02149514A (ja) * 1988-04-06 1990-06-08 Nitto Denko Corp 医薬部材
EP0470007B1 (en) * 1990-08-03 1995-03-15 Terumo Kabushiki Kaisha Wound-covering materials
GB9021674D0 (en) * 1990-10-05 1990-11-21 Ethical Pharma Ltd Transdermal device
US5240917A (en) * 1991-04-03 1993-08-31 Keimowitz Rudolph M Suppression of thromboxane levels by percutaneous administration of aspirin
US5123900A (en) * 1991-08-16 1992-06-23 Bertek, Inc. Moisture permeable double disk
CH686816A5 (de) * 1992-02-04 1996-07-15 Asulab Ag Einrichtung zur Abgabe eines Arzneimittels.
US6071896A (en) * 1992-06-16 2000-06-06 Gundersen Clinic, Ltd. Suppression of thromboxane levels by percutaneous administration of aspirin
DE9219105U1 (de) * 1992-10-31 1998-03-05 Klocke Verpackungs-Service GmbH, 76356 Weingarten Behälter zur Aufnahme von aromatischen Substanzen
AU5596394A (en) * 1992-11-09 1994-06-08 Pharmetrix Corporation Transdermal delivery of ketorolac
FR2709670B1 (fr) * 1993-09-10 1995-10-20 Asulab Sa Dispositif en trois modules pour l'administration transdermique de médicaments par électrophorèse ou iontophorèse.
WO1995024172A1 (en) * 1994-03-07 1995-09-14 Theratech, Inc. Drug-containing adhesive composite transdermal delivery device
DE4423850A1 (de) * 1994-07-07 1996-01-11 Labtec Gmbh Transdermales therapeutisches System zur Applikation von Naloxon
DE19517145C2 (de) * 1995-05-10 2000-02-24 Hexal Pharmaforschung Gmbh Transdermales therapeutisches System (TTS) zur Verabreichung von Testosteron
US5730721A (en) 1996-01-25 1998-03-24 Vesture Corporation Medical applicator and method
US6248789B1 (en) 1996-08-29 2001-06-19 Stuart L. Weg Administration of ketamine to manage pain and to reduce drug dependency
US5800832A (en) * 1996-10-18 1998-09-01 Virotex Corporation Bioerodable film for delivery of pharmaceutical compounds to mucosal surfaces
US6119036A (en) 1997-03-26 2000-09-12 The Board Of Regents Of The University Of Oklahoma Iontophoretic transdermal delivery device
US5919476A (en) * 1997-09-29 1999-07-06 Pmt Corporation Reinforced gel sheeting for scar treatment
DE19743484C1 (de) * 1997-10-01 1999-01-28 Lohmann Therapie Syst Lts Transdermales therapeutisches System mit Schutz vor oraler Applikation und Verfahren zum Schutz einer Person vor Kontamination infolge unzulässiger oraler Applikation toxischer Inhaltsstoffe eines transdermalen therapeutischen Systems
US7011843B2 (en) 1997-10-01 2006-03-14 Lts Lohmann-Therapie Systeme Ag Method for protecting a human being against health impairment by ingestion of a transdermal therapeutic system
US20050048102A1 (en) * 1997-10-16 2005-03-03 Virotex Corporation Pharmaceutical carrier device suitable for delivery of pharmaceutical compounds to mucosal surfaces
US6087341A (en) * 1998-02-12 2000-07-11 The Board Of Trustees Of The Leland Standford Junior University Introduction of nucleic acid into skin cells by topical application
EP1079815B1 (de) * 1998-05-22 2004-10-20 Novosis AG Zeitgesteuert freisetzende wirkstoffhaltige transdermalsysteme
DE19929197A1 (de) * 1999-06-25 2000-12-28 Novosis Pharma Ag Transdermalsysteme zur Abgabe von 5-HT3-Rezeptor-Antagonisten und ihre Verwendung zur antiemitischen Behandlung
DE19934523A1 (de) * 1999-07-22 2001-01-25 Novosis Pharma Ag Transdermalsysteme zur Abgabe von Muscarin-Rezeptor-Antagonisten und ihre Verwendung zur Behandlung von Spasmen der glatten Muskulatur im urologischen Bereich
US7713546B1 (en) * 2001-04-03 2010-05-11 Soft Gel Technologies, Inc. Corosolic acid formulation and its application for weight-loss management and blood sugar balance
USRE44145E1 (en) 2000-07-07 2013-04-09 A.V. Topchiev Institute Of Petrochemical Synthesis Preparation of hydrophilic pressure sensitive adhesives having optimized adhesive properties
US20020119187A1 (en) * 2000-09-29 2002-08-29 Cantor Adam S. Composition for the transdermal delivery of fentanyl
US8449908B2 (en) 2000-12-22 2013-05-28 Alltranz, Llc Transdermal delivery of cannabidiol
US8541021B2 (en) 2001-05-01 2013-09-24 A.V. Topchiev Institute Of Petrochemical Synthesis Hydrogel compositions demonstrating phase separation on contact with aqueous media
EP1390085B1 (en) 2001-05-01 2009-08-05 A.V. Topchiev Institute of Petrochemical Synthesis Hydrogel compositions
US8840918B2 (en) 2001-05-01 2014-09-23 A. V. Topchiev Institute of Petrochemical Synthesis, Russian Academy of Sciences Hydrogel compositions for tooth whitening
US8206738B2 (en) 2001-05-01 2012-06-26 Corium International, Inc. Hydrogel compositions with an erodible backing member
AU2002316053A1 (en) 2001-05-01 2002-11-11 A.V. Topchiev Institute Of Petrochemical Synthesis Two-phase, water-absorbent bioadhesive composition
US20050113510A1 (en) 2001-05-01 2005-05-26 Feldstein Mikhail M. Method of preparing polymeric adhesive compositions utilizing the mechanism of interaction between the polymer components
US20050215727A1 (en) 2001-05-01 2005-09-29 Corium Water-absorbent adhesive compositions and associated methods of manufacture and use
DE10141650C1 (de) 2001-08-24 2002-11-28 Lohmann Therapie Syst Lts Transdermales Therapeutisches System mit Fentanyl bzw. verwandten Substanzen
TWI329105B (en) 2002-02-01 2010-08-21 Rigel Pharmaceuticals Inc 2,4-pyrimidinediamine compounds and their uses
AU2003252075A1 (en) * 2002-07-16 2004-02-02 University Of South Florida Human immunosuppressive protein
EP2130541A3 (en) 2002-07-29 2013-12-18 Rigel Pharmaceuticals, Inc. Methods of treating or preventing autoimmune diseases with 2,4-pyrimidinediamine compounds
NZ540282A (en) 2002-11-18 2008-06-30 Yaupon Therapeutics Inc Analgesic uses of norketamine and ketamine/norketamine prodrugs
CA2729967C (en) * 2002-12-13 2018-01-16 Schering-Plough Healthcare Products, Inc. Use of a transdermal or transmucosal ingredient delivery device
WO2004094457A2 (en) * 2003-04-16 2004-11-04 Arizona Board Of Regents, Acting For And On Behalf Of, Arizona State University Stable rgd peptidomimetic composition
WO2004093788A2 (en) * 2003-04-17 2004-11-04 The Trustees Of Columbia University In The City Ofnew York Desmoglein 4 is a novel gene involved in hair growth
CA2530996C (en) 2003-07-03 2013-05-07 Corium International, Inc. Wound dressing, ingredient delivery device and iv hold-down, and method relating to same
SI1663242T1 (sl) 2003-08-07 2011-09-30 Rigel Pharmaceuticals Inc 2,4-pirimidindiaminske spojine in uporabe kot antiproliferativna sredstva
EP1663168B1 (en) * 2003-09-08 2009-02-11 McNeil AB Nicotine formulations and use thereof
AU2005210637B2 (en) 2004-01-30 2010-09-16 A.V. Topchiev Institute Of Petrochemical Synthesis Rapidly dissolving film for delivery of an active agent
US20050186269A1 (en) * 2004-02-25 2005-08-25 Udell Ronald G. Stabilized feverfew formulations
CA2557532A1 (en) 2004-04-23 2005-11-10 Angela M. Christiano Inhibition of hairless protein mrna
US20050249791A1 (en) * 2004-05-07 2005-11-10 3M Innovative Properties Company Antimicrobial articles
GB2414461B (en) * 2004-05-24 2007-09-12 Mark Rupert Tucker Form-fill-seal process
WO2006017807A2 (en) 2004-08-05 2006-02-16 Corium International, Inc. Adhesive composition
US20060051435A1 (en) * 2004-08-19 2006-03-09 Udell Ronald G Nutritional supplement for body fat reduction
US20060079514A1 (en) * 2004-10-13 2006-04-13 Victory Pharma Incorporated Methods and compositions including methscopolamine bromide
US20060079513A1 (en) * 2004-10-13 2006-04-13 Preston David M Methods and compositions including methscopolamine nitrate
US8252319B2 (en) 2004-10-21 2012-08-28 Durect Corporation Transdermal delivery system for sufentanil
DE602005021909D1 (de) 2004-10-21 2010-07-29 Durect Corp Transdermale verabreichungssysteme
GB2421431B (en) * 2004-12-24 2007-10-10 Aquasol Ltd Dosing systems
US20070104805A1 (en) * 2005-11-01 2007-05-10 Udell Ronald G Compositions of Hoodia Gordonii and Pinolenic Acid Derivatives
AT502717A1 (de) * 2005-11-09 2007-05-15 Omnica Gmbh Pharmazeutische verwendung einer verbindung
GB0523031D0 (en) * 2005-11-11 2005-12-21 Yaupon Therapeutics Enhancement of morphine analgesia by s(-)-norketamine
WO2007065428A1 (en) * 2005-12-08 2007-06-14 Fertin Pharma Low flexural strength transdermal tobacco alkaloid patch
US20090246264A1 (en) * 2005-12-08 2009-10-01 Fertin Pharma Transdermal Tobacco Alkaloid Patch
US8962643B2 (en) 2006-02-24 2015-02-24 Rigel Pharmaceuticals, Inc. Compositions and methods for inhibition of the JAK pathway
EP2007877B1 (en) * 2006-02-28 2013-04-17 The Trustees of Columbia University in the City of New York Methods for compact aggregation of dermal cells
AT503329A1 (de) * 2006-03-02 2007-09-15 Omnica Gmbh Verfahren zur herstellung einer zusammensetzung, welche zumindest ein xantophyll enthält
AT503521A1 (de) * 2006-05-05 2007-11-15 Omnica Gmbh Verwendung eines extraktes von kiwi-frucht
US8278358B2 (en) * 2006-07-06 2012-10-02 Omnica Gmbh Lipoic acid derivatives
RU2504377C2 (ru) 2006-07-21 2014-01-20 БайоДеливери Сайенсиз Интэнэшнл, Инк. Способ трансмукозальной доставки лекарства, средство трансмукозальной доставки лекарства (варианты) и способ лечения боли
JP2008044926A (ja) * 2006-08-14 2008-02-28 Trustees Of Columbia Univ In The City Of New York Ｗｎｔ信号伝達に関係した分泌タンパク質
CA2673125C (en) 2006-10-19 2015-04-21 Rigel Pharmaceuticals, Inc. Compositions and methods for inhibition of the jak pathway
JP5264759B2 (ja) 2006-11-21 2013-08-14 ライジェル ファーマシューティカルズ， インコーポレイテッド ２，４−ピリミジンジアミン化合物のプロドラッグ塩およびそれらの使用
US8623429B2 (en) 2007-03-15 2014-01-07 Omnica Gmbh Stabilized anthocyanin compositions
US7820207B2 (en) * 2007-03-15 2010-10-26 Omnica Gmbh Stabilized anthocyanin compositions
US20080293644A1 (en) * 2007-04-27 2008-11-27 Thomas Eidenberger Guava extract
AU2007353989A1 (en) * 2007-05-31 2008-12-04 Fertin Pharma A/S Transdermal tobacco alkaloid reservoir patch
US8034983B2 (en) * 2007-06-06 2011-10-11 Multi-Tech Specialty Chemicals, Co., Ltd. Process for the preparation of xanthophyll crystals
JP2010535238A (ja) * 2007-07-30 2010-11-18 オールトランツ インコーポレイティド カンナビジオールのプロドラッグ、カンナビジオールのプロドラッグを含む組成物及びその使用方法
EP2234608A2 (en) 2007-12-11 2010-10-06 Viamet Pharmaceuticals, Inc. Metalloenzyme inhibitors using metal binding moieties in combination with targeting moieties
WO2009089380A2 (en) * 2008-01-08 2009-07-16 The Trustees Of Columbia University In The City Of New York Methods for p2ry5 mediated regulation of hair growth and mutants thereof
US20090247619A1 (en) * 2008-03-06 2009-10-01 University Of Kentucky Cannabinoid-Containing Compositions and Methods for Their Use
WO2009131947A2 (en) * 2008-04-21 2009-10-29 Institute For Oneworld Health Compounds, compositions and methods comprising pyridazine derivatives
US8207205B2 (en) * 2008-04-21 2012-06-26 Institute For Oneworld Health Compounds, compositions and methods comprising oxadiazole derivatives
US20090264433A1 (en) * 2008-04-21 2009-10-22 Institute For Oneworld Health Compounds, Compositions and Methods Comprising Triazine Derivatives
US8236838B2 (en) * 2008-04-21 2012-08-07 Institute For Oneworld Health Compounds, compositions and methods comprising isoxazole derivatives
WO2010033626A1 (en) * 2008-09-19 2010-03-25 Institute For Oneworld Health Compounds, compositions and methods comprising imidazole and triazole derivatives
SI2367812T1 (sl) 2008-08-22 2016-01-29 Sanofi (4-(5-aminometil-2-fluoro-fenil)-piperidin-1-il)-(7-fluoro-1-(2-metoksi- etil)-4trifluorometoksi-1H-indol-3-il)metanon kot inhibitor mastocitne triptaze
AR074776A1 (es) 2008-12-18 2011-02-09 Sanofi Aventis Metodo para tratar la degeneracion macular; modulando el sistema inmunitario del paciente
WO2010078369A2 (en) 2008-12-30 2010-07-08 Rigel Pharmaceuticals, Inc. Pyrimidinediamine kinase inhibitors
CA2751884C (en) 2009-01-14 2018-09-25 Corium International, Inc. Transdermal administration of tamsulosin
CN102356075B (zh) 2009-01-23 2015-06-10 里格尔药品股份有限公司 抑制jak途径的组合物和方法
CN102405044A (zh) 2009-02-06 2012-04-04 南加利福尼亚大学 含有单萜的治疗组合物
US8511216B2 (en) * 2009-03-30 2013-08-20 Kanzaki Kokyukoki Mfg. Co., Ltd. Hydraulic actuator unit
US8343976B2 (en) * 2009-04-20 2013-01-01 Institute For Oneworld Health Compounds, compositions and methods comprising pyrazole derivatives
WO2011005660A1 (en) 2009-07-08 2011-01-13 Valocor Therapeutics, Inc. Tofa analogs useful in treating dermatological disorders or conditions
US20110034415A1 (en) * 2009-07-20 2011-02-10 Thomas Eidenberger Walnut extracts for nutraceutical applications
US20110038904A1 (en) * 2009-08-17 2011-02-17 Silipos Inc. Gel Product
FR2955324A1 (fr) 2010-01-15 2011-07-22 Sanofi Aventis [4-(5-aminomethyl-phenyl)-piperidin-1-yl]-1h-indol-3-yl]-methanones disubstituees
WO2011053468A1 (en) 2009-10-30 2011-05-05 Sanofi-Aventis Amino-benzoic acid derivatives for use in the treatment of dihydrogenase-related disorders
US20110144200A1 (en) 2009-12-14 2011-06-16 Thomas Eidenberger Combination of carotenoids and epi-lutein
AR079661A1 (es) 2009-12-23 2012-02-08 Sanofi Aventis Derivados de n-(4f-3-{1-[indol-3-carbonil]piperidin-4-il}bencil)acetamidas
JP2013515725A (ja) 2009-12-23 2013-05-09 サノフイ ［４［４−（５−アミノメチル−２−フルオロ−フェニル）−ピペリジン−１−イル］−（１ｈ−ピロロ−ピリジン−イル）−メタノン類及びその合成
WO2011130716A2 (en) 2010-04-16 2011-10-20 Access Pharmaceuticals, Inc. A nanostructures containing vitamin b12 for facilitated delivery of drugs across biological barriers
EP2560643A1 (en) 2010-04-20 2013-02-27 Institute for OneWorld Health Compounds, compositions and methods comprising 1,3,4-oxadiazole derivatives
WO2011133600A1 (en) 2010-04-20 2011-10-27 Institute For Oneworld Health Compounds, compositions and methods comprising pyridazine sulfonamide derivatives
CN103097374B (zh) 2010-04-24 2015-01-07 威尔金制药有限公司 金属酶抑制剂化合物
JP6073221B2 (ja) 2010-07-28 2017-02-01 ライジェル ファーマシューティカルズ， インコーポレイテッド Ｊａｋ経路の阻害のための組成物および方法
CA2816088A1 (en) 2010-10-28 2012-05-03 Viamet Pharmaceuticals, Inc. Metalloenzyme inhibitor compounds
CN103370076A (zh) 2010-11-02 2013-10-23 纽约市哥伦比亚大学托管会 治疗毛发脱落疾病的方法
CA2817691C (en) 2010-11-13 2020-09-01 Viamet Pharmaceuticals, Inc. Metalloenzyme inhibitor compounds
KR20130101576A (ko) 2010-12-13 2013-09-13 비아멧 파마슈티컬즈, 인코포레이티드 금속효소 억제제 화합물
PH12013501078A1 (en) 2010-12-20 2018-03-21 Colgate Palmolive Co Gelatin encapsulated oral care composition containing hydrophilic active hydrophobic structuring agent and oil carrier
CA2828360A1 (en) 2011-02-25 2012-08-30 The United States Of America, As Represented By The Secretary, Departmen T Of Health And Human Services Chrysophaentin analogs that inhibit ftsz protein
KR20140026396A (ko) 2011-03-08 2014-03-05 어섹스 팔마큐티칼스 인코포레이티드 생물학적 막을 가로질러 활성물질의 전달을 위한 표적화된 나노담체 시스템
CN103764647B (zh) 2011-06-19 2016-05-18 威尔金制药有限公司 金属酶抑制剂化合物
WO2012177603A2 (en) 2011-06-19 2012-12-27 Viamet Pharmaceuticals, Inc. Metalloenzyme inhibitor compounds
EA025266B1 (ru) 2011-06-23 2016-12-30 Ваймет Фармасьютикалс, Инк. Соединения, ингибирующие металлоферменты
WO2013019169A1 (en) 2011-08-01 2013-02-07 Institute For Oneworld Health Phosphate prodrugs
SG11201401446RA (en) 2011-08-18 2014-09-26 Biodelivery Sciences Int Inc Abuse-resistant mucoadhesive devices for delivery of buprenorphine
EP2750767A4 (en) 2011-09-02 2015-10-14 Univ Columbia CAMKII, IP3R, CALCINEURIN, P38 AND MK2 / 3 INHIBITORS FOR THE TREATMENT OF METABOLISM DISORDER IN CONNECTION WITH ADIPOSITAS
HUE037899T2 (hu) 2011-12-11 2018-09-28 Viamet Pharmaceuticals Nc Inc Metalloenzim inhibitor vegyületek
US9901539B2 (en) 2011-12-21 2018-02-27 Biodelivery Sciences International, Inc. Transmucosal drug delivery devices for use in chronic pain relief
CN104136427B (zh) 2012-01-20 2017-03-01 威尔金制药有限公司 金属酶抑制剂化合物
CA2865504A1 (en) 2012-03-23 2013-09-26 Oxigene, Inc. Compositions and methods for inhibition of cathepsins
CN104334191A (zh) 2012-03-29 2015-02-04 纽约市哥伦比亚大学托管会 治疗毛发脱落疾病的方法
WO2013173506A2 (en) 2012-05-16 2013-11-21 Rigel Pharmaceuticals, Inc. Method of treating muscular degradation
JP2016506930A (ja) 2013-01-25 2016-03-07 ライジェル ファーマシューティカルズ， インコーポレイテッド 炎症性腸疾患を処置するための化合物および方法
KR20150129847A (ko) 2013-03-15 2015-11-20 더 트러스티스 오브 컬럼비아 유니버시티 인 더 시티 오브 뉴욕 융합 단백질 및 이들의 방법
WO2015089310A1 (en) * 2013-12-11 2015-06-18 Atkinson Oscar Occlusive skin covering
US20150174386A1 (en) * 2013-12-19 2015-06-25 Kimberly-Clark Worldwide, Inc. Transdermal device containing microneedles
WO2015134920A1 (en) 2014-03-07 2015-09-11 The Arizona Board Of Regents On Behalf Of The University Of Arizona Non-narcotic crmp2 peptides targeting sodium channels for chronic pain
JP2017514790A (ja) 2014-03-19 2017-06-08 ヴィアメット ファーマスーティカルズ，インコーポレイテッド 抗真菌化合物の調製方法
EP3778644A3 (en) 2014-12-23 2021-06-02 The Trustees of Columbia University in the City of New York Fgfr-tacc fusion proteins and methods thereof
CN107428724B (zh) 2015-03-19 2021-07-02 迈科维亚医药公司 抗真菌化合物及制备方法
JP6994454B2 (ja) 2015-08-04 2022-01-14 ライジェル ファーマシューティカルズ， インコーポレイテッド ベンズアゾール化合物ならびに該化合物の作製方法および使用方法
AU2016323782B2 (en) 2015-09-18 2020-11-26 Nqp 1598, Ltd. Antifungal compound process
US10188750B1 (en) 2015-10-23 2019-01-29 University Of South Florida Self-replicating cell selective gene delivery compositions, methods, and uses thereof
KR102240920B1 (ko) 2015-12-30 2021-04-16 브이피에스-3, 엘엘씨 금속 효소 억제 화합물
CA3016464A1 (en) 2016-03-08 2017-09-14 Soo-Young Kang Long lasting cosmetic compositions
CA3028997A1 (en) 2016-06-27 2018-01-04 Rigel Pharmaceuticals, Inc. 2,4-diamino-pyrimidine compounds and method for making and using the compounds
EP3478091B1 (en) 2016-06-29 2024-03-20 Halo Life Science, LLC Method of preparing a low odor dicholinium ellagate salt and other low odor organic salts of choline
EP4212523A1 (en) 2016-10-26 2023-07-19 Rigel Pharmaceuticals, Inc. Pyrazole amide compounds as irak inhibitors
EP3532470B1 (en) 2016-10-26 2022-12-07 Rigel Pharmaceuticals, Inc. Oxazole derivatives for use as irak inhibitors and method for their preparation
EP3562306B1 (en) 2016-12-29 2025-02-26 Ji Xing Pharmaceuticals Hong Kong Limited Metalloenzyme inhibitor compounds
RU2764666C2 (ru) 2016-12-29 2022-01-19 Селенити Терапьютикс (Бермуда), Лтд. Соединения, ингибирующие металлоферменты
GB201708579D0 (en) * 2017-05-30 2017-07-12 Univ Of Wolverhampton Science Park Ltd Wound dressing
CN111032642B (zh) 2017-06-29 2023-07-18 里格尔药品股份有限公司 激酶抑制剂及制造和使用方法
GB2561262B (en) * 2017-07-13 2019-03-20 Dentmed Ltd A targeted drug delivery pad
JP7244495B2 (ja) 2017-09-13 2023-03-22 リビング プルーフ インコーポレイテッド 長期持続性の化粧品組成物
CA3074845A1 (en) 2017-09-13 2019-03-21 Living Proof, Inc. Color protectant compositions
WO2019099966A1 (en) 2017-11-20 2019-05-23 Living Proof, Inc. Properties for achieving long-lasting cosmetic performance
US20210292410A1 (en) 2017-12-07 2021-09-23 Morphosys Ag Treatment paradigm for an anti-cd19 antibody and venetoclax combination treatment
AU2019257739B2 (en) 2018-04-27 2025-01-09 Living Proof, Inc. Long lasting cosmetic compositions
DK3788044T3 (da) 2018-05-03 2023-10-02 Rigel Pharmaceuticals Inc RIP1-hæmmende forbindelser og fremgangsmåder til fremstilling og anvendelse heraf
PE20210414A1 (es) 2018-05-03 2021-03-04 Rigel Pharmaceuticals Inc Compuestos inhibidores de rip1 y metodos para preparar y usar los mismos
WO2020092845A1 (en) 2018-11-01 2020-05-07 Rigel Pharmaceuticals, Inc. Method and composition embodiments for treating acute myeloid leukemia
AU2020207051B2 (en) 2019-01-08 2025-07-24 Corxel Pharmaceuticals Hong Kong Limited Metalloenzyme inhibitor compounds
US11090346B2 (en) 2019-05-28 2021-08-17 Inbold Inc. Cannabinoid composition and method of sublingual, buccal and oral mucosa delivery
US20200377518A1 (en) 2019-05-29 2020-12-03 Rigel Pharmaceuticals, Inc. Method of preventing and treating thrombosis
MX2022001596A (es) 2019-08-08 2022-03-11 Rigel Pharmaceuticals Inc Compuestos y metodos para tratar sindrome de liberacion de citocinas.
CA3147444A1 (en) 2019-08-14 2021-02-18 Rigel Pharmaceuticals, Inc. Method of blocking or ameliorating cytokine release syndrome
US11370787B2 (en) 2019-08-30 2022-06-28 Rigel Pharmaceuticals, Inc. Pyrazole compounds, formulations thereof, and a method for using the compounds and/or formulations
TW202122397A (zh) 2019-09-06 2021-06-16 美商雷傑製藥公司 Ｒｉｐ１抑制性化合物及用於製備和使用其之方法
PE20221628A1 (es) 2019-09-06 2022-10-19 Rigel Pharmaceuticals Inc Compuestos inhibidores de rip1 y metodos para hacer y utilizar los mismos
MX2022005509A (es) 2019-11-07 2022-10-18 Rigel Pharmaceuticals Inc Compuestos inhibidores de rip1 heterociclicos.
US12357623B2 (en) 2021-03-03 2025-07-15 Rigel Pharmaceuticals, Inc. Method for treating a disease or condition using a pyrazole compound or formulation thereof
TW202300490A (zh) 2021-03-11 2023-01-01 美商雷傑製藥公司 雜環rip1激酶抑制劑
WO2023136749A1 (ru) * 2022-01-11 2023-07-20 Павел Владимирович КОРЧАГИН Система и способ обеспечения безопасности для держателей банковских карт
WO2023183377A1 (en) 2022-03-23 2023-09-28 Rigel Pharmaceuticals, Inc. Pyrimid-2-yl-pyrazole compounds as irak inhibitors
WO2023192479A1 (en) 2022-03-31 2023-10-05 Rigel Pharmaceuticals, Inc. Tricyclic irak inhibitors

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3598122A (en) * 1969-04-01 1971-08-10 Alza Corp Bandage for administering drugs
AU1147476A (en) * 1975-03-19 1977-09-01 Procter & Gamble Controlled release article
US4725272A (en) * 1981-06-29 1988-02-16 Alza Corporation Novel bandage for administering beneficial drug
EP0184910B1 (en) * 1984-11-15 1992-09-30 Hercon Laboratories Corporation Device for controlled release drug delivery
US4752478A (en) * 1984-12-17 1988-06-21 Merck & Co., Inc. Transdermal system for timolol
DE3587616D1 (de) * 1984-12-22 1993-11-11 Sanol Arznei Schwarz Gmbh Wirkstoffpflaster.
US4597961A (en) * 1985-01-23 1986-07-01 Etscorn Frank T Transcutaneous application of nicotine
US4756710A (en) * 1985-04-05 1988-07-12 Merck & Co., Inc. pH-Mediated drug delivery system
US4645502A (en) * 1985-05-03 1987-02-24 Alza Corporation Transdermal delivery of highly ionized fat insoluble drugs
GB8512358D0 (en) * 1985-05-16 1985-06-19 Euro Celtique Sa Transdermal delivery system

Also Published As

Publication number Publication date
AU618085B2 (en) 1991-12-12
DE68915291T2 (de) 1994-09-01
WO1989007959A1 (en) 1989-09-08
JP2716231B2 (ja) 1998-02-18
JPH03503636A (ja) 1991-08-15
AU3289589A (en) 1989-09-22
IN172748B (enExample) 1993-11-20
DE68915291D1 (de) 1994-06-16
EP0508979A1 (en) 1992-10-21
GB8804164D0 (en) 1988-03-23
KR970009723B1 (ko) 1997-06-17
ES2052071T3 (es) 1994-07-01
EP0508979B1 (en) 1994-05-11
KR900700153A (ko) 1990-08-11
US5254346A (en) 1993-10-19
EP0336543A1 (en) 1989-10-11

Similar Documents

Publication Publication Date Title
ZA891403B (en) Occlusive body for administering a physiologically active substance
GR1002252B (en) A novel therapeutic active compound and preparation method therefore.
GB8828477D0 (en) Medical aerosol formulations
AU2550288A (en) A medical device for introduction into a body cavity
GB2232892B (en) Occlusive body for administering a physiologically active substance
AU3926589A (en) Pharmaceutical compounds exhibiting somatostatin-like activity
GR3023006T3 (en) Medicament for augmenting fetal hemoglobin
ZA898201B (en) Gestodene-containing agent for transdermal administration
EP0294053A3 (en) Physiologically active agent for agricultural use
EP0370673A3 (en) Therapeutic agent for aids
EP0450100A4 (en) Physiologically active peptide
AU8303687A (en) Composition for administration through a body cavity
ZA899948B (en) Pharmaceutical preparation
EP0455818A4 (en) Physiologically active substance be-16627
EP0366614A3 (en) Pharmaceutically active dithioketene derivatives
GB8902424D0 (en) Medicinal formulations
AU8640491A (en) Device for administering a physiologically active substance to the gastro-intestinal tract
GB8805811D0 (en) Pharmaceutically active compounds
IE882467L (en) Pharmaceutical preparation for external use
GB8901158D0 (en) Administering drugs
GB8914384D0 (en) A capsule for a medicament
BG48198A1 (en) Active sonorifying body
SG171194G (en) Pharmaceutically active dithioketene derivatives
GB8821120D0 (en) Therapeutic substance
GB8814742D0 (en) Medicament inhalation device